Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | CD38 | P28907 | 3/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.34 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | GLS | O94925 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19973954 | 0.81 | DPP4 (0.43) | TBXAS1CYP1A2 | |
| SCHEMBL4207114 | 0.80 | MBOAT4 (0.38) | CYP2C19 | |
| SCHEMBL19973982 | 0.79 | CYP24A1 (0.35) | CD38TBXAS1ADORA2A | |
| SCHEMBL26597451 | 0.78 | HDAC1 (0.34) | TBXAS1 | |
| SCHEMBL20511745 | 0.78 | CYP19A1 (0.38) | TBXAS1CYP1A2CYP2C19 | |
| SCHEMBL26597482 | 0.77 | SMN1; SMN2 (0.44) | CD38 | |
| SCHEMBL20509607 | 0.76 | PDE10A (0.47) | CYP1A2 | |
| SCHEMBL19973543 | 0.76 | SMN1; SMN2 (0.50) | TBXAS1CYP1A2CYP2C19 | |
| SCHEMBL4218428 | 0.76 | CD38 (0.43) | P2RX7CD38CYP1A2CYP2C19 | |
| SCHEMBL4027132 | 0.75 | HMOX1 (0.48) | MAOBCYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3601216-B1 | SUBSTITUTED DIHYDROINDENE-4-CARBOXAMIDES AND ANALOGS THEREOF, AND METHODS USING SAME FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | ARBUTUS BIOPHARMA CORP (CA) | 2023-10-25 | — | — | EP | disclosed |
| EP-3601216-B1 | SUBSTITUTED DIHYDROINDENE-4-CARBOXAMIDES AND ANALOGS THEREOF, AND METHODS USING SAME FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | ARBUTUS BIOPHARMA CORP (CA) | 2023-10-25 | — | — | EP | disclosed |
| EP-3601216-A1 | SUBSTITUTED DIHYDROINDENE-4-CARBOXAMIDES AND ANALOGS THEREOF, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018172852-A1 | SUBSTITUTED DIHYDROINDENE-4-CARBOXAMIDES AND ANALOGS THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-09-27 | — | — | WO | disclosed |